Database for Clinical and Anamnestic Data in Pulmonary Hypertension

NCT01607502 | Recruiting

• 1 other identifier: 23-408 ex 10/11
• Study Type: observational
• Target: 900
• Locations: 1 country
• Sites: 1

Brief Summary

Pulmonary hypertension (PH) is defined as a pulmonary arterial mean pressure (meanPAP) ≥ 25 mmHg measured in the right heart catheterization. There are different forms of PH defined in the classification of Dana Point 2008. PH is diagnosed with right heart catheterization but there are other non invasive methods which can be used for screening like the echocardiography, stress echocardiography and cardio pulmonary exercise testing. In the diagnosis process and in the follow up of PH patients biomarkers like NTproBNP are helpful. There are no specific biomarkers for the disease which can make the diagnosis process easier and predict prognosis. The systematic data collection in a data base provides better information about patients in daily routine and clinical studies as well as in the design of new studies.

Conditions

Pulmonary Hypertension

Keywords

Pulmonary hypertension; database; biomarker

Outcome Measures

Primary Outcomes (1)

• Collecting data in a PH patient database

  Retrospective and prospective data input and constant update

  After one year: first analysis of retrospectively collected data. Ongoing data collection: new data of patients who are already in the database, new patients (3-4 years)

Study Arms (1)

Patients of our outpatient clinic

Patients who have an investigation in our outpatient clinic for pulmonary hypertension like a echocardiography, a right heart catheterization or a cardio pulmonary exercise testing

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who come to our outpatient clinic with pulmonary haypertension, symptoms that may be caused by pulmonary hypertension and patients at risk for pulmonary hypertension

You may qualify if:

• patients with pulmonary hypertension
• patients at risk for getting pulmonary hypertension
• patients who have symptoms which my be due to pulmonary hypertension when we have their written informed consent.

You may not qualify if:

• patients without written informed consent

Sponsors & Collaborators

• Medical University of Graz: lead

Study Sites (1)

Medical University of Graz

Graz, 8010, Austria

RECRUITING

Related Publications (1)

• Kovacs G, Avian A, Foris V, Tscherner M, Kqiku X, Douschan P, Bachmaier G, Olschewski A, Matucci-Cerinic M, Olschewski H. Use of ECG and Other Simple Non-Invasive Tools to Assess Pulmonary Hypertension. PLoS One. 2016 Dec 28;11(12):e0168706. doi: 10.1371/journal.pone.0168706. eCollection 2016.

  PMID: 28030578 DERIVED

Biospecimen

Retention: SAMPLES WITH DNA

Blood samples are collected and stored anonymously in our biobank if patients give their informed consent containing the option of DNA analysis.

MeSH Terms

Conditions

Hypertension, Pulmonary

Condition Hierarchy (Ancestors)

Lung Diseases; Respiratory Tract Diseases; Hypertension; Vascular Diseases; Cardiovascular Diseases

Study Officials

• Horst Olschewski, MD

  Medical University of Graz

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Horst Olschewski, MD

CONTACT

+43-316-385-12183; horst.olschewski@medunigraz.at

Maria Tscherner, MD

CONTACT

+43-316-385-12183; m.tscherner@medunigraz.at

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 13, 2012
• First Posted: May 30, 2012
• Study Start: July 1, 2010
• Primary Completion (Estimated): July 1, 2027
• Study Completion (Estimated): July 1, 2027
• Last Updated: January 15, 2026

Record last verified: 2026-01

Locations

AU (1)